Expert Analysis

Lymphomas

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Lymphomas

Program Director: Roy A. Beveridge, MD

Faculty:

Alexandra M. Levine, MD
Carol S. Portlock, MD
Julie M. Vose, MD

Moderator: Robert S. Mocharnuk, MD

CME CREDIT INFORMATION

Release Date: 02/28/08

Expiration Date: 02/27/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recently reported clinical data on emerging treatments for follicular lymphoma
Explain the use of imaging for guiding treatment decisions in non-Hodgkin’s lymphoma and Hodgkin’s disease
Discuss efficacy and safety data from recent studies including patients with aggressive lymphomas

Topics covered include:

HyperCVAD Plus Rituximab in Newly-Diagnosed Mantle Cell Lymphoma Patients
Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support for MCL
Durable Responses With Bortezomib in Patients With Relapsed or Refractory MCL
Bendamustine Plus Rituximab vs CHOP Plus Rituximab for First-Line Treatment of Patients With Indolent and MCL
⁹⁰Y-Ibritumomab Consolidation for First Remission in Advanced FL
Rituximab Followed by Salvage High-Dose Therapy With ASCT in Patients With FL
Abbreviated Chemoimmunotherapy After R-CHOP for Limited-Stage, PET-Negative Diffuse Large B-Cell Lymphoma
Rituximab Prior to Autologous Hematopoietic Stem Cell Transplantation Improves PFS and OS in DLBCL
Single Agent Everolimus Active in Relapsed Aggressive Non-Hodgkin’s Lymphoma
Central Nervous System Prophylaxis Not Protective Against CNS Relapse in Aggressive NHL
Limited and Extended Rituximab in Nodular Lymphocyte–Predominant Hodgkin's Disease
FDG-PET Guided Consolidative Radiotherapy in Patients With Advanced-Stage Hodgkin’s Lymphoma
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.